SCSAP MEMBER SPOTLIGHT

Arul Chinnaiyan, M.D., Ph.D.,

Bio: Dr. Chinnaiyan is a molecular pathologist and physician scientist at the leading edge of translational cancer research and precision oncology. He is an Investigator of the Howard Hughes Medical Institute, American Cancer Society Research Professor, and Director of the Michigan Center for Translational Pathology.  He has received several honors including the Paul Marks Prize for Cancer Research and the NCI Outstanding Investigator Award; he was also
inducted into the AACR Academy Class of 2020. He is a member of the American Society for Clinical Investigation, Association of American Physicians, American Academy of Arts and Sciences, National Academy of Inventors, National Academy of Medicine, and the National Academy of Sciences. Most recently he was awarded the 2022 Sjöberg Prize for cancer research by the Royal Swedish Academy of Sciences.

Dr. Chinnaiyan is best known for the discovery of TMPRSS2-ETS gene fusions in a majority of prostate cancers, the first causative gene fusion in a common solid tumor. This landmark discovery was made using a bioinformatics approach to detect outlier genes in an aggregated tumor gene expression database developed by his group. In 2011, he established the first integrative, comprehensive clinical sequencing approach for advanced cancer patients called MI-ONCOSEQ, which has served as a paradigm for cancer precision medicine. He has also been taking advantage of integrative sequencing efforts to understand the non-coding genome of cancer, especially in the area of biomarker and therapeutic development.

RECENT PUBLICATIONS

 

Pan-cancer proteogenomics characterization of tumor immunity.

Petralia F, Ma W, Yaron TM, Caruso FP, Tignor N, Wang JM, Charytonowicz D, Johnson JL, Huntsman EM, Marino GB, Calinawan A, Evangelista JE, Selvan ME, Chowdhury S, Rykunov D, Krek A, Song X, Turhan B, Christianson KE, Lewis DA, Deng EZ, Clarke DJB, Whiteaker JR, Kennedy JJ, Zhao L, Segura RL, Batra H, Raso MG, Parra ER, Soundararajan R, Tang X, Li Y, Yi X, Satpathy S, Wang Y, Wiznerowicz M, González-Robles TJ, Iavarone A, Gosline SJC, Reva B, Robles AI, Nesvizhskii AI, Mani DR, Gillette MA, Klein RJ, Cieslik M, Zhang B, Paulovich AG, Sebra R, Gümüş ZH, Hostetter G, Fenyö D, Omenn GS, Cantley LC, Ma’ayan A, Lazar AJ, Ceccarelli M, Wang P; Clinical Proteomic Tumor Analysis Consortium.Cell. 2024 Feb 29;187(5):1255-1277.e27. doi: 10.1016/j.cell.2024.01.027. Epub 2024 Feb 14.PMID: 38359819 Free article.

 

Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies.

He T, Xiao L, Qiao Y, Klingbeil O, Young E, Wu XS, Mannan R, Mahapatra S, Eyunni S, Tien JC, Wang X, Zheng Y, Kim N, Zheng H, Hou S, Su F, Miner SJ, Mehra R, Cao X, Sekhar AC, Samajdar S, Ramachandra M, Parolia A, Vakoc CR, Chinnaiyan AM.bioRxiv [Preprint]. 2024 Jan 25:2024.01.22.576669. doi: 10.1101/2024.01.22.576669.PMID: 38328238 Free PMC article. Preprint.
 

 

Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients-A Tale of Two Cities: Sequencing Analysis Reveals Dual Lineage Markers Capturing the 2 Cellular Populations of HOT.

Wang XM, Mannan R, Zhang Y, Chinnaiyan A, Rangaswamy R, Chugh S, Su F, Cao X, Wang R, Skala SL, Hafez KS, Vaishampayan U, Mckenney J, Picken MM, Gupta S, Alaghehbandan R, Tretiakova M, Argani P, Chinnaiyan AM, Dhanasekaran SM, Mehra R.Am J Surg Pathol. 2024 Feb 1;48(2):163-173. doi: 10.1097/PAS.0000000000002152. Epub 2023 Nov 24.PMID: 37994665 Free PMC article.